BERYL DRUGS LIMITED

Regd. Off.: Ground Floor, 133, Kanchan Bagh, **Indore** - 452001 (M.P.)

Tel. : (0731) 2517677 | **E-mail :** beryldrugs25@yahoo.com | **CIN :** L02423MP1993PLC007840

Date: 07.08.2025

To,

The Secretary,
Department of Corporate Services,
Bombay Stock Exchange Limited (BSE),
Phiroze Jeejeebhoy Towers, Dalal Street,
Mumbai – 400001

Scrip Code: 524606

Sub.: Disclosure of Regulation 30 read with Part- A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sirs,

Pursuant to Regulation 30 read with Part- A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Board of Directors in its 2/2025-2026Board Meeting held on 07.08.2025has approved the Unaudited Financial Results of the Company for the Quarter ended30.06.2025.

We hereby request you to kindly acknowledge the receipts of same.

Thanking You,

Yours Sincerely

For Beryl Drugs Limited

BERYL DRUGS LTD.
Director

Sudhir Sethi
Chairman& Director
DIN: 00090172

BERYL DRUGS LIMITED
Gr. Floor, 133, Kanchan Bagh, Indore (M.P.) – 452 001.
Tel./ Fax 0731-2517677
E-mail : beryldrugs25@yahoo.com

ANNEXURE I

Submission of Unaudited/ Audited Financial Result by Companies Other than Banks

Part I

(Rs in Lakhs) except per share data

Statement of Unaudited Result for the Quarter ended 30/06/2025

	Particulars	Quarter ended			Year ended
		3 months ended (30-06-2025)	Preceding 3 months ended (31-03-2025)	Corresponding 3 months ended in the previous year (30-06-2024)	Previous year ended (31-03-2025)
(Refer Notes Below)		Unaudited	Audited	Unaudited	Audited
1	**Revenue From Operations**				
	Net sales or Revenue from Operations	479.43	397.36	624.91	2114.62
	Other operating revenues	4.15	124.60	3.82	140.86
	Total Revenue from operations (net)	483.58	521.96	628.73	2255.49
2	**Expenses**				
(a)	Cost of materials consumed	220.87	246.48	336.14	1112.14
(b)	Purchases of stock-in-trade	0.00	0.00	0.00	0.00
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-18.34	35.25	9.11	-33.70
(d)	Employee benefit expense	53.39	59.44	49.64	221.22
(e)	Finance costs	10.09	7.90	20.77	52.97
(f)	Depreciation and amortisation expense	38.08	31.65	28.17	124.56
(g)	Other Expenses	172.52	131.06	135.33	691.72
	Total expenses	**476.61**	**511.78**	**579.16**	**2168.92**
3	**Profit (loss) from operations before exceptional items and tax**	**6.97**	**10.18**	**49.57**	**86.57**
4	**Exceptional items**	0.00	0.00	0.00	0.00
5	Profit (loss) before tax	**6.97**	**10.18**	**49.57**	**86.57**
6	**Tax Expense**				
	Current tax	15.00	-14.58	13.75	20.11
	Adjustments in respect of current income tax of proir year	0.00	0.00	0.00	-1.09
	Deferred tax	-10.14	9.58	-0.97	9.66
	Total Tax Expanses	**4.86**	**-5.00**	**12.78**	**28.68**
7	Net Profit (loss) for the period from continuing operations	2.11	15.19	36.79	57.89
8	Net Profit (loss) from discontinuing operations before tax	**0.00**	**0.00**	**0.00**	**0.00**
9	Tax Expense of discontinuing operations	0.00	0.00	0.00	0.00
10	Net Profit (loss) from discontinuing operations after tax	0.00	0.00	0.00	0.00
11	**Net Profit (loss) for the Period**	2.11	15.19	36.79	57.89
12	**Other comprehensive income**				
	Items that will not be reclassified to profit or loss	0.24	-0.62	0.27	1.16
	Items that will be reclassified to profit or loss				0.00
	Total Other Comprehensive Income	0.24	-0.62	0.27	1.16
13	**Total Comprehensive Income**	**2.35**	**14.57**	**37.06**	**59.05**
14	**Details of equity share capital**				
	Paid-up equity share capital	507.17	507.17	507.17	507.17
	Face value of equity share capital	10.00	10.00	10.00	10.00
15	**Earnings per share (of Rs. 10 each)- for continuing operations**				
i	Basic	0.04	0.30	0.73	1.14
ii	Diluted	0.04	0.30	0.73	1.14

Notes :

1. The above financial results have been prepared in accordance with the recognition and mesurement principles stated therein prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Agreement Regulation.

2. The above results for the quarter ended 30th June 2025 which have been subjected to Limited Review by Statutory Auditors of the Company were reviewed and recommended by the Audit Committee and subsequently by the Board of Directors at its meeting held on 07th August,2025 in terms of regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) , Regulation, 2015, as amended.

3. The Income from Operations is from one segment namely "Pharmaceutical Industry" as per Ind AS 108"Operating Segments"

4. The figures for the quarter ended March 31, 2025 are balancing figures between audited figures in respect of full financial year ended March 31, 2025 and the unaudited published figure up to December 31, 2024 being the end of third quarter of the financial year which were subjected to limited review.

5. The figures for the previous periods have been regrouped/ reclassified wherever necessary to confirm to current period classification.

6. A part of manufacturing facility is under suspension and upgardation. Hence, Turnover is decrease by virtue of said suspension, therefore turnover is affected in whole Quarter.

6. Depreciation is provided on Written down value method on the estimated remaining useful lives of the assets.

7. Revenue from Operations is net of GST.

8. Earnings per Share amount is Shown in Rupees.

For and behalf of the Board

Sanjay Sethi
Managing Director

Place : Indore
Date : 07.08.2025

Subhash Chand Jain Anurag & Associates

Chartered Accountants
104, Archana Apartment, 8-B, Ratlam Kothi,Indore-452001 (MP)
PH # 2519439, 2527682 FAX # 0731 2519116
Mob. No. : +91-9302123882
Email: scjainca2004@yahoo.com

Independent Auditor's Review Report on Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

The Board of Directors
Beryl Drugs Limited
Gr. Floor, 133, Kanchan Bagh
Indore (M.P.)-452001

1. We have reviewed the accompanying statement of unaudited financial results of **Beryl Drugs Limited** ("the Company") for the quarter ended June 30, 2025 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended (the "Listing Regulations'}.

2. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors and prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (lnd AS 34) prescribed under section 133 of the Companies Act, 2013 read with rule 3 of Companies (Indian Accounting Standard) rules 2015, as amended read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410,"Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consist of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain

SUBHASH CHAND JAIN ANURAG & ASSOCIATES
FRN. 004733C
INDORE
Chartered Accountants

assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33, Regulation52 and Regulation 54 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. Attention is drawn to Notes to the statement:

   a) **Note No. 4**: The figures for the quarter ended March 31, 2025 are balancing figures between audited figures in respect of full financial year ended March 31, 2025 and the unaudited published figure up to December 31, 2024 being the end of third quarter of the said relevant financial year which were subjected to limited review by us.

   b) **Note No. 6:** A part of manufacturing facility is under suspension and upgardation. Hence, Turnover is decrease by virtue of said suspension, therefore turnover is affected in whole Quarter.

For Subhash Chand Jain Anurag & Associates
Chartered Accounts
FRN: 004733C

SUBHASH CHAND JAIN ANURAG & ASSOCIATES FRN. 004733C INDORE Chartered Accountants

(Akshay Jain)
Partner
M.No.447487
UDIN: 25447487BMICUC1257

Date: 07/08/2025
Place: Indore